- Home
- SBFM vs ESNT Comparison
SBFM vs ESNT Comparison
Compare SBFM & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- ESNT
- Stock Information
- Founded
- SBFM 2006
- ESNT 2008
- Country
- SBFM United States
- ESNT Bermuda
- Employees
- SBFM N/A
- ESNT N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- ESNT Property-Casualty Insurers
- Sector
- SBFM Health Care
- ESNT Finance
- Exchange
- SBFM Nasdaq
- ESNT Nasdaq
- Market Cap
- SBFM 4.9M
- ESNT N/A
- IPO Year
- SBFM N/A
- ESNT 2013
- Fundamental
- Price
- SBFM $1.51
- ESNT $55.54
- Analyst Decision
- SBFM Strong Buy
- ESNT Buy
- Analyst Count
- SBFM 1
- ESNT 7
- Target Price
- SBFM $15.00
- ESNT $61.71
- AVG Volume (30 Days)
- SBFM 4.3M
- ESNT 774.1K
- Earning Date
- SBFM 05-19-2025
- ESNT 05-09-2025
- Dividend Yield
- SBFM N/A
- ESNT 2.23%
- EPS Growth
- SBFM N/A
- ESNT 5.38
- EPS
- SBFM N/A
- ESNT 6.85
- Revenue
- SBFM $34,874,283.00
- ESNT $1,242,904,000.00
- Revenue This Year
- SBFM $192.48
- ESNT $4.19
- Revenue Next Year
- SBFM N/A
- ESNT $4.79
- P/E Ratio
- SBFM N/A
- ESNT $8.11
- Revenue Growth
- SBFM 44.75
- ESNT 12.00
- 52 Week Low
- SBFM $1.17
- ESNT $51.61
- 52 Week High
- SBFM $33.60
- ESNT $65.33
- Technical
- Relative Strength Index (RSI)
- SBFM 43.22
- ESNT 49.80
- Support Level
- SBFM $1.17
- ESNT $55.16
- Resistance Level
- SBFM $1.59
- ESNT $56.85
- Average True Range (ATR)
- SBFM 0.17
- ESNT 1.87
- MACD
- SBFM 0.04
- ESNT 0.10
- Stochastic Oscillator
- SBFM 70.89
- ESNT 75.00
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.